Education and debate

Lesson of the Week: Bilateral cataracts and glaucoma induced by long term use of steroid eye drops

Department of Ophthalmology, Royal Liverpool University Hospital Trust, Liverpool L7 8XP.

The adverse effects of topical steroid administration to the eye are well known and include glaucoma, cataract, exacerbation of corneal infection, and systemic effects secondary to systemic absorption.^1,2 Previous reports have highlighted the potential reactivation or exacerbation of herpes simplex keratitis, together with an increased risk of other infections.^3,4 We report a case of steroid induced glaucoma and cataracts (with irreversible visual loss) following prolonged unsupervised administration of topical steroid eyedrops.

Case report

A 47 year old woman presented to the accident and emergency department with a chronic history of irritable eyes, a right upper lid chalazion, and decreasing vision over three months. The ophthalmic history was of left amblyopia and an episode of acute anterior uveitis several years previously. This uveitis had been treated at St Paul's Eye Hospital with topical steroids for four weeks. The only relevant medical history was of hypothyroidism.

On examination . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Advanced glaucomatous visual loss and oral steroids

Vikas Chadha, Iain Cruickshank, Robert Swingler, and Roshini Sanders
BMJ 2008 337: a670. [Extract] [Full Text]

Topical steroids for ocular disease

N Rowson
BMJ 1994 309: 740. [Extract] [Full Text]

Periocular steroid ointments may cause ocular damage

C J McLean, R F J Lobo, and D J Brazier
BMJ 1994 309: 543. [Extract] [Full Text]

This article has been cited by other articles:

• Unoki, N, Nishijima, K, Kita, M, Suzuma, K, Watanabe, D, Oh, H, Kimura, T, Sakamoto, A, Yoshimura, N (2009). Randomised controlled trial of posterior sub-Tenon triamcinolone as adjunct to panretinal photocoagulation for treatment of diabetic retinopathy. Br J Ophthalmol 93: 765-770 [Abstract] [Full text]  
• Chadha, V., Cruickshank, I., Swingler, R., Sanders, R. (2008). Advanced glaucomatous visual loss and oral steroids. BMJ 337: a670-a670 [Full text]  
• Kuppermann, B. D., Blumenkranz, M. S., Haller, J. A., Williams, G. A., Weinberg, D. V., Chou, C., Whitcup, S. M., for the Dexamethasone DDS Phase II Study Group, (2007). Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular Edema. Arch Ophthalmol 125: 309-317 [Abstract] [Full text]  
• Whitmore, S. E., Leiner, S., Corcoran, T. R., Bai, T. R., Garbe, E., Suissa, S., Cumming, R. G., Mitchell, P., Leeder, S. R. (1997). Inhaled Corticosteroids and the Risk of Cataracts. NEJM 337: 1554-1555 [Full text]  
• Garbe, E., LeLorier, J., Boivin, J.-F., Suissa, S. (1997). Inhaled and Nasal Glucocorticoids and the Risks of Ocular Hypertension or Open-angle Glaucoma. JAMA 277: 722-727 [Abstract]  
• Rowson, N (1994). Topical steroids for ocular disease. BMJ 309: 740-740 [Full text]  
• McLean, C J, Lobo, R F J, Brazier, D J (1994). Periocular steroid ointments may cause ocular damage. BMJ 309: 543a-543 [Full text]